Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects

NCT ID: NCT00244751

Last Updated: 2017-12-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 265 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-11-02
• Study Completion Date: 2008-03-13

Brief Summary

The purpose of this study is to examine the safety and effectiveness of GI262570 compared to placebo (a pill that looks exactly like GI262570 but contains no active medicine) in improving specific tests that indicate the degree of liver fibrosis (scarring). Subjects who are enrolled in the study must have had prior treatment with interferon (either pegylated or standard interferon) plus ribavirin for at least 12 weeks to treat their hepatitis C, but either failed to clear the virus or didn't tolerate the treatment.

Conditions

Cirrhosis, Liver

Keywords

Hepatitis C liver fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT

Study Groups

GI262570 0.5 mg

Participants received GI262570 0.5 milligrams (mg) tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.

Group Type: EXPERIMENTAL

GI262570 0.5 mg

Intervention Type: DRUG

GI262570 0.5 mg

GI262570 1.0 mg

Participants received GI262570 1.0 mg tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.

Group Type: EXPERIMENTAL

GI262570 1.0 mg

Intervention Type: DRUG

GI262570 1.0 mg

Placebo

Participants received matching placebo tablet once daily approximately 30 minutes prior to breakfast for 52 weeks. Participant received their morning dose at the site on Weeks 2, 16, 28, 40, and 52.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo

Interventions

GI262570 0.5 mg

GI262570 0.5 mg

Intervention Type: DRUG

GI262570 1.0 mg

GI262570 1.0 mg

Intervention Type: DRUG

Placebo

Placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• A subject will be eligible for inclusion in this study only if all of the following criteria apply:
• Age between 40 and 70 years, inclusive.
• Documented positive serology for HCV antibody by a second generation or higher assay.
• Serum HCV RNA positive and HCV viral Genotype 1 at pre-screening visit.
• Ishak fibrosis score of 2, 3 or 4.
• Failure to achieve sustained virologic response (SVR) with previous interferon (standard or pegylated) and ribavirin treatment administered at a minimum dose of 3mU three times weekly or equivalent, for at least 12 weeks. Reasons for failure may include failure to respond to treatment or intolerability to optimal treatment. Prior treatment with interferon/ribavirin must have been discontinued at least 11 months prior to the biopsy date.
• Male or female; a female is eligible to enter and participate in this study if she is of:

1. non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal); or,

2. child-bearing potential, has a negative serum pregnancy test at screen, and agrees to one of the following:

• Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for a time interval after completion or premature discontinuation from the study to account for elimination of the investigational drug, (a minimum of 5 half-lives or longer if the pharmacodynamic profile of the investigational drug warrants a longer time period); or,
• Female sterilization; or,
• Has a male partner who is sterilized; or,
• Implants of levonorgestrel; or,
• Injectable progestogen; or,
• Oral contraceptive (combined or progestogen only) , must be stable for 3 months prior to study entry; or,
• Any intrauterine device (IUD) with published data showing that the lowest expected failure rate is less than 1% per year (not all IUDs meet this criterion); or,
• Any other methods with published data showing that the lowest expected failure rate for that method is less than 1% per year; or,
• Barrier method only if used in combination with any of the above acceptable methods.
• Availability and willingness of subject to provide written informed consent.

Exclusion Criteria

A subject will not be eligible for inclusion in this study if any of the following criteria apply:

• History of ascites, variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial peritonitis or other signs of hepatic decompensation.
• Current or historical evidence suggestive of ischemic heart disease or other cardiovascular disease that in the investigator's opinion may adversely impact the safety of the subject during the conduct of the study. Evidence suggestive of cardiovascular disease may come from a number of sources, including clinical history, physical exam, electrocardiogram, laboratory testing, and radiographic procedures.
• New York Heart Association (NYHA) Functional Class 1, 2, 3, or 4 cardiac status
• Co-infection with HBV or HIV.
• Liver histology consistent with any other co-existing cause of chronic liver disease.
• Documented evidence of a hepatic mass lesion suspicious for hepatocellular carcinoma.
• Alpha-fetoprotein > 200ng/mL at pre-screening.
• Inadequate hematologic function defined by any of the following:

Hemoglobin (<12.5 g/dL for men)(<12.0 g/dL for women)

Absolute Neutrophil Count (ANC) (<1.0 x 10^9/L) Platelets (<130X/10^9/L)

• Inadequate renal function defined as:

Serum creatinine (>1.5mg/dL (≥130mmol/L)) Calculated creatinine clearance as calculated by Cockcroft and Gault (<60mL/min)

• Serum ALT level ≥5 x ULN.
• Albumin <3.2g/dL.
• Total bilirubin >1.2 x ULN.
• Prothrombin time > 15 seconds or International normalized ratio (INR) > 1.3.
• Organ, stem cell, or bone marrow transplant.
• Serious concurrent medical illness that in the investigator's opinion might interfere with therapy. This includes significant systemic illnesses (other than liver disease) such as chronic pancreatitis.
• Active systemic autoimmune disorder.
• A pre-existing condition interfering with normal gastrointestinal anatomy or motility, and/or renal function that could interfere with the absorption, metabolism, and/or excretion of the study drugs.
• Other medical conditions that, in the investigator's opinion, might interfere with compliance with therapy, participation in the study or interpretation of results.
• Pregnancy (or lactation) or, in subjects capable of bearing children, inability/unwillingness to practice adequate contraception.
• Females of child-bearing potential (post-puberty) unwilling or unable to have pregnancy testing at any study visit.
• Therapy with systemic cytotoxic agents, immunomodulators, or immunosuppressive therapy requiring use of more than 5mg of prednisone (or its equivalent) per day.
• Therapy with a systemic antiviral agent (with the exception of prophylaxis or treatment of influenza or chronic HSV) within the past 30 days.
• Concurrent participation in another clinical trial in which the subject is or will be exposed to another investigational or a non-investigational drug or device within 30 days of the screening visit.
• Current therapy or anticipated need for therapy with hypoglycemic drugs (e.g., insulin, sulfonylurea or metformin).
• Known hypersensitivity to GI262570, or to any component of the GI262570 soft gelatin capsules, dispersion tablets or the sodium salt tablet or to PPARg agonists.
• A history of hepatotoxicity to TZDs and/or a history of severe edema or medically serious fluid-related events associated with the use of TZDs.
• Use of other PPAR agonists (e.g., rosiglitazone, pioglitazone) within 1 year from the start of dosing.
• Active alcohol abuse within the past 1 year.
• Use of illegal drugs in the past 1 year. 30a. Macular edema or history of macular edema.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Birmingham, Alabama, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

North Little Rock, Arkansas, United States

GSK Investigational Site

Bakersfield, California, United States

GSK Investigational Site

La Jolla, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Newport Beach, California, United States

GSK Investigational Site

Pasadena, California, United States

GSK Investigational Site

Sacramento, California, United States

GSK Investigational Site

San Clemente, California, United States

GSK Investigational Site

San Francisco, California, United States

GSK Investigational Site

Santa Clara, California, United States

GSK Investigational Site

Englewood, Colorado, United States

GSK Investigational Site

Washington D.C., District of Columbia, United States

GSK Investigational Site

Fort Lauderdale, Florida, United States

GSK Investigational Site

Miami, Florida, United States

GSK Investigational Site

Orlando, Florida, United States

GSK Investigational Site

Sarasota, Florida, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Marietta, Georgia, United States

GSK Investigational Site

Honolulu, Hawaii, United States

GSK Investigational Site

Indianapolis, Indiana, United States

GSK Investigational Site

Iowa City, Iowa, United States

GSK Investigational Site

Louisville, Kentucky, United States

GSK Investigational Site

Lutherville-Timonium, Maryland, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Worcester, Massachusetts, United States

GSK Investigational Site

Ann Arbor, Michigan, United States

GSK Investigational Site

Detroit, Michigan, United States

GSK Investigational Site

St Louis, Missouri, United States

GSK Investigational Site

Binghamton, New York, United States

GSK Investigational Site

Manhasset, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Syracuse, New York, United States

GSK Investigational Site

The Bronx, New York, United States

GSK Investigational Site

Chapel Hill, North Carolina, United States

GSK Investigational Site

Durham, North Carolina, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Cincinnati, Ohio, United States

GSK Investigational Site

Cleveland, Ohio, United States

GSK Investigational Site

Tulsa, Oklahoma, United States

GSK Investigational Site

Hershey, Pennsylvania, United States

GSK Investigational Site

Lancaster, Pennsylvania, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Houston, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Charlottesville, Virginia, United States

GSK Investigational Site

Fairfax, Virginia, United States

GSK Investigational Site

Richmond, Virginia, United States

GSK Investigational Site

Richmond, Virginia, United States

GSK Investigational Site

Herston, Queensland, Australia

GSK Investigational Site

Camperdown, Victoria, Australia

GSK Investigational Site

Clayton, Victoria, Australia

GSK Investigational Site

Fitzroy, Melbourne, Victoria, Australia

GSK Investigational Site

Heidelberg, Victoria, Australia

GSK Investigational Site

Melbourne, Victoria, Australia

GSK Investigational Site

Calgary, Alberta, Canada

GSK Investigational Site

Vancouver, British Columbia, Canada

GSK Investigational Site

Victoria, British Columbia, Canada

GSK Investigational Site

Winnipeg, Manitoba, Canada

GSK Investigational Site

Halifax, Nova Scotia, Canada

GSK Investigational Site

London, Ontario, Canada

GSK Investigational Site

Ottawa, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Brno - Bohunice, , Czechia

GSK Investigational Site

Hradec Králové, , Czechia

GSK Investigational Site

Prague, , Czechia

GSK Investigational Site

Prague, , Czechia

GSK Investigational Site

Freiburg im Breisgau, Baden-Wurttemberg, Germany

GSK Investigational Site

Heidelberg, Baden-Wurttemberg, Germany

GSK Investigational Site

Tübingen, Baden-Wurttemberg, Germany

GSK Investigational Site

Erlangen, Bavaria, Germany

GSK Investigational Site

Frankfurt am Main, Hesse, Germany

GSK Investigational Site

Hanover, Lower Saxony, Germany

GSK Investigational Site

Bonn, North Rhine-Westphalia, Germany

GSK Investigational Site

Düsseldorf, North Rhine-Westphalia, Germany

GSK Investigational Site

Münster, North Rhine-Westphalia, Germany

GSK Investigational Site

Homburg, Saarland, Germany

GSK Investigational Site

Leipzig, Saxony, Germany

GSK Investigational Site

Halle, Saxony-Anhalt, Germany

GSK Investigational Site

Berlin, , Germany

GSK Investigational Site

Hamburg, , Germany

GSK Investigational Site

Haifa, , Israel

GSK Investigational Site

Jerusalem, , Israel

GSK Investigational Site

Nazareth, , Israel

GSK Investigational Site

Petah Tikva, , Israel

GSK Investigational Site

Rehovot, , Israel

GSK Investigational Site

Tel Aviv, , Israel

GSK Investigational Site

Bandar Tun Razak, Cheras, , Malaysia

GSK Investigational Site

Kepong, , Malaysia

GSK Investigational Site

Auckland, , New Zealand

GSK Investigational Site

San Juan, , Puerto Rico

GSK Investigational Site

Bucharest, , Romania

GSK Investigational Site

Bucharest, , Romania

GSK Investigational Site

Cluj-Napoca, Cluj, , Romania

GSK Investigational Site

Moscow, , Russia

GSK Investigational Site

Moscow, , Russia

GSK Investigational Site

Moscow, , Russia

GSK Investigational Site

Moscow, , Russia

GSK Investigational Site

Saint Petersburg, , Russia

GSK Investigational Site

Singapore, , Singapore

GSK Investigational Site

Daegu, , South Korea

GSK Investigational Site

Pusan, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Seoul, , South Korea

GSK Investigational Site

Kaohsiung City, , Taiwan

GSK Investigational Site

Kaohsiung City, , Taiwan

GSK Investigational Site

Taipei, , Taiwan

GSK Investigational Site

Taoyuan District, , Taiwan

Countries

Finland; United States; Australia; Canada; Czechia; Germany; Israel; Malaysia; New Zealand; Puerto Rico; Romania; Russia; Singapore; South Korea; Taiwan

Other Identifiers

FBX104114

Identifier Type: -

Identifier Source: org_study_id